Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIANER study of neratinib diarrhea prophylaxis strategies in early HER2-positive, hormone receptor-positive breast cancer
2019-001559-38Phase 2Active
- Sponsor
- GEICAM
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of neratinib in breast cancer (3 arms), sponsored by GEICAM. Primary endpoint: Incidence of neratinib discontinuations due to diarrhoea at the end of 3 cycles of neratinib treatment. Started Nov 2021; status: active.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-001559-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001559-38.